The heterogeneity of lymphomas results in numerous treatment options, including both autologous and allogeneic hematopoietic cell transplantation. However, the type of transplantation, the timing the procedure, and the selection of suitable patients for transplant continue to evolve.
Methods
We reviewed the current medical literature to provide a succinct synthesis for the most common types of lymphoma and the indications for transplantation.
Results
This review discusses the outcomes of autologous and allogeneic transplantation for patients with diffuse large B-cell lymphoma, follicular lymphoma, HIV-associated lymphomas, mantle cell lymphoma, T-cell lymphoma, and Hodgkin lymphoma.
Conclusions
Each of these histologies differs in the indications and timing for transplantation. However, ongoing clinical trials support the continuing role of both autologous and allogeneic transplantation for lymphoma management.
References
1.
PazdurR., WagmanL.D., CamphausenK.A. eds. Cancer Management: A Multidisciplinary Approach. Medical, Surgical & Radiation Oncology.13 ed.Norwalk, CT: UBM Medica; 2010.
2.
PasquiniM.C., WangZ.. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2010. http://www.cibmtr.org. Accessed August 2, 2011.
3.
SantiniG., SalvagnoL., LeoniP.. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.J Clin Oncol.1998; 16(8): 2796–2802.
4.
GianniA.M., BregniM., SienaS.. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.N Engl J Med.1997; 336(18): 1290–1297.
5.
HaiounC., LepageE., GisselbrechtC.. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol — a groupe d'Etude des Lymphomes de l'Adulte study.J Clin Oncol.2000; 18(16): 3025–3030.
6.
BaldisseraR.C., NucciM., VigoritoA.C.. Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.Acta Haematol.2006; 115(1-2): 15–21.
7.
VitoloU., LiberatiA.M., CabrasM.G.. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial.Haematologica.2005; 90(6): 793–801.
8.
BetticherD.C., MartinelliG., RadfordJ.A.. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).Ann Oncol.2006; 17(10): 1546–1552.
9.
OlivieriA., SantiniG., PattiC.. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG.Ann Oncol.2005; 16(12): 1941–1948.
10.
MartelliM., GherlinzoniF., De RenzoA.. Early autologous stemcell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.J Clin Oncol.2003; 21(7): 1255–1262.
11.
Kluin-NelemansH.C., ZagonelV., AnastasopoulouA.. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.J Natl Cancer Inst.2001; 93(1): 22–30.
12.
KaiserU., UebelackerI., AbelU.. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma.J Clin Oncol.2002; 20(22): 4413–4419.
13.
GisselbrechtC., LepageE., MolinaT.. Shortened first-line highdose chemotherapy for patients with poor-prognosis aggressive lymphoma.J Clin Oncol.2002; 20(10): 2472–2479.
14.
OlianskyD.M., CzuczmanM., FisherR.I.. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review.Biol Blood Marrow Transplant.2011; 17(1): 20–47.e30.
15.
MilpiedN., DeconinckE., GaillardF.. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stemcell support.N Engl J Med.2004; 350(13): 1287–1295.
16.
StiffP.J., UngerJ.M., CookJ.. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with highintermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL).J Clin Oncol.2011; 29(suppl): 8001. Abstract.
17.
PhilipT., GuglielmiC., HagenbeekA.. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.N Engl J Med.1995; 333(23): 1540–1545.
18.
JantunenE., CanalsC., RambaldiA.. Autologous stem cell transplantation in elderly patients (≥ or = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry.Haematologica.2008; 93(12): 1837–1842.
19.
BuadiF.K., MicallefI.N., AnsellS.M.. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.Bone Marrow Transplant.2006; 37(11): 1017–1022.
20.
JantunenE., ItalaM., JuvonenE.. Autologous stem cell transplantation in elderly (≥ 60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis.Bone Marrow Transplant.2006; 37(4): 367–372.
21.
LazarusH.M., CarrerasJ., BoudreauC.. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).Biol Blood Marrow Transplant.2008; 14(12): 1323–1333.
22.
CoiffierB., LepageE., BriereJ.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med.2002; 346(4): 235–242.
23.
FeugierP., Van HoofA., SebbanC.. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.J Clin Oncol.2005; 23(18): 4117–4126.
24.
PfreundschuhM., TrumperL., OsterborgA.. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.Lancet Oncol.2006; 7(5): 379–391.
25.
KewalramaniT., ZelenetzA.D., NimerS.D.. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.Blood.2004; 103(10): 3684–3688.
26.
FlinnI.W., O'DonnellP.V., GoodrichA.. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.Biol Blood Marrow Transplant.2000; 6(6): 628–632.
27.
BenekliM., HahnT., ShafiF.. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.Bone Marrow Transplant.2003; 32(2): 139–143.
28.
HorwitzS.M., NegrinR.S., BlumeK.G.. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.Blood.2004; 103(3): 777–783.
29.
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT) (BMT CTN 0401).http://clinicaltrials.gov/ct2/show/NCT00329030. Accessed June 8, 2011.
30.
LazarusH.M., ZhangM.J., CarrerasJ.. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.Biol Blood Marrow Transplant.2010; 16(1): 35–45.
31.
van KampenR.J., CanalsC., SchoutenH.C.. Allogeneic stemcell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stemcell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.J Clin Oncol.2011; 29(10): 1342–1348.
32.
MorschhauserF., RadfordJ., Van HoofA.. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.J Clin Oncol.2008; 26(32): 5156–5164.
33.
SebbanC., MounierN., BrousseN.. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).Blood.2006; 108(8): 2540–2544.
34.
LenzG., DreylingM., SchiegnitzE.. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stemcell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.J Clin Oncol.2004; 22(24): 4926–4933.
35.
LenzG., DreylingM., SchiegnitzE.. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.Blood.2004; 104(9): 2667–2674.
36.
LadettoM., De MarcoF., BenedettiF.. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.Blood.2008; 111(8): 4004–4013.
37.
GyanE., FoussardC., BertrandP.. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median followup of 9 years.Blood.2009; 113(5): 995–1001.
38.
SebbanC., BriceP., DelarueR.. Impact of rituximab and/or highdose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.J Clin Oncol.2008; 26(21): 3614–3620.
39.
SchoutenH.C., QianW., KvaloyS.. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.J Clin Oncol.2003; 21(21): 3918–3927.
40.
RohatinerA.Z., NadlerL., DaviesA.J.. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.J Clin Oncol.2007; 25(18): 2554–2559.
41.
BriceP., SimonD., BouabdallahR.. High-dose therapy with autologous stemcell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol.Ann Oncol.2000; 11(12): 1585–1590.
42.
van BesienK., LoberizaFRJr, BajorunaiteR.. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.Blood.2003; 102(10): 3521–3529.
43.
HosingC., SalibaR.M., McLaughlinP.. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.Ann Oncol.2003; 14(5): 737–744.
44.
BiermanP.J., SweetenhamJ.W., LoberizaFRJr. Syngeneic hematopoietic stemcell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation — The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.J Clin Oncol.2003; 21(20): 3744–3753.
45.
TomblynM.R., EwellM., BredesonC.. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-hodgkin lymphoma beyond first complete response or first partial response.Biol Blood Marrow Transplant.2011; 17(7): 1051–1057.
46.
SheaT., JohnsonJ., WesterveltP.. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.Biol Blood Marrow Transplant.2011; 17(9): 1395–1403.
47.
KhouriI.F., McLaughlinP., SalibaR.M.. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.Blood.2008; 111(12): 5530–5536.
48.
CorradiniP., DoderoA., FarinaL.. Long-term follow-up of patients affected by relapsed lymphomas receiving reduced-intensity conditioning (RIC) regimen followed by allogeneic stem cell transplantation (Allo-SCT): an update of the phase II study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)Blood (ASH Annual Meeting Abstracts).2008; 112(11): 3303.
49.
Blood and Marrow Transplant Clinical Trials Network. Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response.https://web.emmes.com/study/bmt2/reports/reports.htm. Accessed August 2, 2011.
50.
EngelsE.A., BiggarR.J., HallH.I.. Cancer risk in people infected with human immunodeficiency virus in the United States.Int J Cancer.2008; 123(1): 187–194.
51.
LimS.T., KarimR., NathwaniB.N.. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.J Clin Oncol.2005; 23(19): 4430–4438.
52.
KrishnanA., MolinaA., ZaiaJ.. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas.Blood.2005; 105(2): 874–878.
53.
SpitzerT.R., AmbinderR.F., LeeJ.Y.. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.Biol Blood Marrow Transplant.2008; 14(1): 59–66.
54.
BalsalobreP., Diez-MartinJ.L., ReA.. Autologous stemcell transplantation in patients with HIV-related lymphoma.J Clin Oncol.2009; 27(13): 2192–2198.
55.
High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN 0803). http://clinicaltrials.gov/ct2/show/NCT01141712. Accessed June 8, 2011.
56.
HuzickaI.. Could bone marrow transplantation cure AIDS?: review.Med Hypotheses.1999; 52(3): 247–257.
57.
GuptaV., TomblynM., PedersenT.L.. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research.Biol Blood Marrow Transplant.2009 Jul;15(7): 864–871.
58.
GhielminiM., ZuccaE.. How I treat mantle cell lymphoma.Blood.2009; 114(8): 1469–1476.
59.
RomagueraJ.E., FayadL.E., FengL.. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.Br J Haematol.2010; 150(2): 200–208.
60.
KettererN., SallesG., EspinouseD.. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma.Ann Oncol.1997; 8(7): 701–704.
61.
StewartD.A., VoseJ.M., WeisenburgerD.D.. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma.Ann Oncol.1995; 6(3): 263–266.
62.
MilpiedN., GaillardF., MoreauP.. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience.Bone Marrow Transplant.1998; 22(7): 645–650.
63.
VandenbergheE., Ruiz de ElviraC., LoberizaF.R.. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.Br J Haematol.2003; 120(5): 793–800.
64.
DreylingM., LenzG., HosterE.. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.Blood.2005; 105(7): 2677–2684.
65.
MangelJ., LeitchH.A., ConnorsJ.M.. Intensive chemotherapy and autologous stemcell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.Ann Oncol.2004; 15(2): 283–290.
66.
RitchieD.S., SeymourJ.F., GriggA.P.. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.Ann Hematol.2007; 86(2): 101–105.
67.
VoseJ., LoberizaF., BiermanP.. Mantle cell lymphoma (MCL): induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (M-C) (± rituximab) improves results of autologous stem cell transplant in first remission.J Clin Oncol (ASCO Annual Meeting Proceedings Part I).2006; 24(18S June 20 suppl): 7511. Abstract.
68.
GeislerC.H., KolstadA., LaurellA.. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.Blood.2008; 112(7): 2687–2693.
69.
GeislerC.H., KolstadA., LaurellA.. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).Blood.2010; 115(8): 1530–1533.
70.
DamonL.E., JohnsonJ.L., NiedzwieckiD.. Immunochemotherapy and autologous stemcell transplantation for untreated patients with mantlecell lymphoma: CALGB 59909.J Clin Oncol.2009; 27(36): 6101–6108.
71.
LaudiN., AroraM., BurnsL.. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma.Am J Hematol.2006; 81(7): 519–524.
72.
KrögerN., HoffknechtM., DregerP.. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy.Bone Marrow Transplant.1998; 21(1): 55–57.
73.
MarisM.B., SandmaierB.M., StorerB.E.. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.Blood.2004; 104(12): 3535–3542.
74.
TamC.S., BassettR., LedesmaC.. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.Blood.2009; 113(18): 4144–4152.
75.
CookG., SmithG.M., KirklandK.. Outcome following reducedintensity allogeneic stem cell transplantation (RIC alloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant.2010; 16(10): 1419–1427.
76.
VoseJ., ArmitageJ., WeisenburgerD.. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.J Clin Oncol.2008; 26(25): 4124–4130.
77.
CorradiniP., TarellaC., ZallioF.. Longterm follow-up of patients with peripheral T-cell lymphomas treated upfront with high-dose chemotherapy followed by autologous stem cell transplantation.Leukemia.2006; 20(9): 1533–1538.
78.
RodríguezJ., CondeE., GutiérrezA.. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group.Eur J Haematol.2007; 79(1): 32–38.
79.
MercadalS., BrionesJ., XicoyB.. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stemcell transplantation in previously untreated patients with peripheral T-cell lymphoma.Ann Oncol.2008; 19(5): 958–963.
80.
ReimerP., RüdigerT., GeissingerE.. Autologous stemcell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.J Clin Oncol.2009; 27(1): 106–113.
81.
FeylerS., PrinceH.M., PearceR.. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study.Bone Marrow Transplant.2007; 40(5): 443–450.
82.
KyriakouC., CanalsC., GoldstoneA.. High-dose therapy and autologous stemcell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.J Clin Oncol.2008; 26(2): 218–224.
83.
ChenA.I., McMillanA., NegrinR.S.. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.Biol Blood Marrow Transplant.2008; 14(7): 741–747.
84.
Le GouillS., MilpiedN., BuzynA.. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.J Clin Oncol.2008; 26(14): 2264–2271.
85.
CorradiniP., DoderoA., ZallioF.. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.J Clin Oncol.2004; 22(11): 2172–2176.
86.
ShustovA.R., GooleyT.A., SandmaierB.M.. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.Br J Haematol.2010; 150(2): 170–178.
LinchD.C., WinfieldD., GoldstoneA.H.. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.Lancet.1993; 341(8852): 1051–1054.
89.
ArakelyanN., BerthouC., DesablensB.. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.Cancer.2008; 113(12): 3323–3330.
90.
SchmitzN., PfistnerB., SextroM.. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stemcell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.Lancet.2002; 359(9323): 2065–2071.
91.
SweetenhamJ.W., TaghipourG., MilliganD.. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant.1997; 20(9): 745–752.
92.
BiermanP.J., AndersonJ.R., FreemanM.B.. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.Ann Oncol.1996; 7(2): 151–156.
93.
ChopraR., McMillanA.K., LinchD.C.. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.Blood.1993; 81(5): 1137–1145.
94.
SirohiB., CunninghamD., PowlesR.. Long-term outcome of autologous stemcell transplantation in relapsed or refractory Hodgkin's lymphoma.Ann Oncol.2008; 19(7): 1312–1319.
95.
GopalA.K., MetcalfeT.L., GooleyT.A.. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.Cancer.2008; 113(6): 1344–1350.
96.
MajhailN.S., BajorunaiteR., LazarusH.M.. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.Br J Haematol.2009; 147(1): 129–139.
SarinaB., CastagnaL., FarinaL.. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.Blood.2010; 115(18): 3671–3677.
ThomsonK.J., PeggsK.S., SmithP.. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation.Bone Marrow Transplant.2008; 41(9): 765–770.
102.
SuredaA., RobinsonS., CanalsC.. Reduced-intensity conditioning compared with conventional allogeneic stemcell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.J Clin Oncol.2008; 26(3): 455–462.
103.
BurroughsL.M., O'DonnellP.V., SandmaierB.M.. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.Biol Blood Marrow Transplant.2008; 14(11): 1279–1287.
104.
AnderliniP., SalibaR., AcholonuS.. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M. D. Anderson Cancer Center experience.Haematologica.2008; 93(2): 257–264.
105.
KhouriI.F., SalibaR.M., HosingC.. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL).Blood (ASH Annual Meeting Abstracts).2006; 108: 315. Abstract.
106.
ShimoniA., ZwasS.T., OksmanY.. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.Exp Hematol.2007; 35(4): 534–540.
107.
KrishnanA., NademaneeA., FungH.C.. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.J Clin Oncol.2008; 26(1): 90–95.
108.
Shimabukuro-VornhagenA., JostingA., HübelK.. Yttrium-90 ibritu-momab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma.J Clin Oncol.2008; 26(May 20 suppl): 8615. Abstract.
109.
DecaudinD., MounierN., TillyH.. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma: a GELA phase II prospective study.Clin Lymphoma Myeloma Leuk.2011; 11(2): 212–218.
110.
VoseJ.M., BiermanP.J., EnkeC.. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stemcell transplantation for relapsed non-Hodgkin's lymphoma.J Clin Oncol.2005; 23(3): 461–467.
111.
VoseJ., BiermanP., BociekG.. Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation.J Clin Oncol (ASCO Annual Meeting Proceedings Part I).2007; 25(18S June 20 suppl): 8013. Abstract.
112.
NademaneeA., FormanS., MolinaA.. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.Blood.2005; 106(8): 2896–2902.
113.
WinterJ.N., InwardsD.J., SpiesS.. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.J Clin Oncol.2009; 27(10): 1653–1659.
114.
PressO.W., EaryJ.F., GooleyT.. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.Blood.2000; 96(9): 2934–2942.
